Crinetics Pharmaceuticals Awarded $2.8 Million SBIR Grant to Support Development of Acromegaly Drug Candidate CRN00808
13 juil. 2017 13h00 HE
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, July 13, 2017 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc., a rare disease therapeutics company focused on endocrine disorders and endocrine-related cancers, announced today that...
Chiasma Reports First Quarter 2017 Results
05 mai 2017 08h00 HE
|
Chiasma, Inc.
WALTHAM, Mass., May 05, 2017 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ:CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic...
Strongbridge Biopharma plc Provides Corporate and Financial Update
23 déc. 2016 08h03 HE
|
Strongbridge Biopharma plc
~ Expands Rare Disease Portfolio through Acquisition of U.S. Rights to KEVEYIS®, the First and Only FDA-Approved Treatment for Hyperkalemic, Hypokalemic, and Related Variants of Primary Periodic...
Strongbridge Biopharma plc to Participate in the JMP Securities Life Sciences Conference and 3rd Annual ROTH Healthcare Day in London
14 juin 2016 07h30 HE
|
Strongbridge Biopharma plc
DUBLIN, Ireland and TREVOSE, Pa., June 14, 2016 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (NASDAQ:SBBP), a global rare disease biopharmaceutical company focused on the development and...
Chiasma Joins Patient Organizations Worldwide in Support of Rare Disease Day
29 févr. 2016 08h00 HE
|
Chiasma, Inc.
NEWTON, Mass., Feb. 29, 2016 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ:CHMA), a late-stage biopharmaceutical company, today announced its support for Rare Disease Day 2016. In honor of Rare...
Chiasma to Present at Upcoming Investor Conferences
25 févr. 2016 08h00 HE
|
Chiasma, Inc.
NEWTON, Mass., Feb. 25, 2016 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ:CHMA), a late-stage biopharmaceutical company developing Mycapssa™ (octreotide) capsules, a new investigational oral drug for...